文献速递胸部CTPETMR

小细胞肺癌的分子特征与治疗进展:影像学启示

Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications.
PubMed 文献 · Radiology · 2022-10-25

本文综述小细胞肺癌(约占肺癌15%)的分子分型、新兴系统治疗(含免疫检查点抑制剂)及其影像学表现。影像在诊断、分期和疗效监测中至关重要,新治疗带来新的反应模式和毒性表现。文章还讨论了影像组学和机器学习的未来方向。

要点

  • 小细胞肺癌分子分型指导精准治疗,影像需关注治疗相关新表现。
  • 免疫检查点抑制剂可导致非典型反应模式和免疫相关毒性,阅片需警惕。
  • 影像组学和机器学习是SCLC影像的未来方向。

核心结论

  • 小细胞肺癌分子特征和新兴系统治疗对影像诊断、分期和疗效监测提出新要求。

研究设计与样本

  • 本文为最新综述,旨在提供SCLC分子分型、新兴系统治疗及其影像学意义的最新信息。

临床应用与阅片要点

  • 阅片需结合分子分型及治疗方案,识别免疫治疗相关反应模式和毒性表现。
  • 影像在SCLC诊断、分期和治疗监测中不可或缺,新药时代作用增强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Small cell lung cancer (SCLC) is a highly aggressive malignancy with exceptionally poor prognosis, comprising approximately 15% of lung cancers. Emerging knowledge of the molecular and genomic landscape of SCLC and recent successful clinical applications of new systemic agents have allowed for precision oncology treatment approaches. Imaging is essential for the diagnosis, staging, and treatment monitoring of patients with SCLC. The role of imaging is increasing with the approval of new treatment agents, including immune checkpoint inhibitors, which lead to novel imaging manifestations of response and toxicities. The purpose of this state-of-the-art review is to provide the reader with the latest information about SCLC, focusing on the subtyping of this malignancy (molecular characterization) and the emerging systemic therapeutic approaches and their implications for imaging. The review will also discuss the future directions of SCLC imaging, radiomics and machine learning.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Park, Tseng, Sholl, et al. Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications. Radiology. 2022. PMID: 36283111. doi:10.1148/radiol.220585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。